Pfizer's prostate cancer drug combination receives FDA priority review, with a decision expected by late 2026.

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...

A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has been accepted for Priority Review by the US FDA. The application is to ...

Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...

Cult heroes of youth culture; Renton, Sick Boy, Begbie, Spud, Tommy, and Kelly are back, alongside an ensemble cast and a ...

Return of the rave: How London's nightlife evolved to meet a new generation - Venues may have closed, but London’s nightlife ...

Malcolm Waite, who was four times over legal limit when his car hit woman, could be freed from jail after four years ...